MedTrace Logo

Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI

NCT02700633 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2016-03-07

No results posted yet for this study

Summary

Pacemaker requirement in the immediate post procedure phase following TAVI is approximately 20% depending on device type and patient characteristics. There is a signal from recent studies suggesting increased risk of sudden cardiac / unexplained death in the first 30-60 days. This study aims to address whether there is a mortality advantage to having a pacemaker in the short term

Conditions

  • TAVI

Interventions

DEVICE

Pacemaker

Sponsors & Collaborators

  • Royal Sussex County Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700633 on ClinicalTrials.gov